276702-15-9

276702-15-9 structure

Name: SB 332235
Chemical Name: SB-332235
CAS Number: 276702-15-9
Molecular Formula: C₁₃H₁₀Cl₃N₃O₄S
Molecular Weight: 410.660
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2018-07-12 23:00:54
Modify Date: 2024-01-10 18:59:49
SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].

Name	SB-332235
Synonyms	6-Chloro-3-{[(2,3-dichlorophenyl)carbamoyl]amino}-2-hydroxybenzenesulfonamide SB-332235 5HLP8UVL8M Benzenesulfonamide, 6-chloro-3-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-2-hydroxy-

Description	SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> CXCR Research Areas >> Inflammation/Immunology Signaling Pathways >> Immunology/Inflammation >> CXCR
In Vitro	SB-332235 (1-100 μM; 48 hours) inhibits viability of AML cell lines[2]. Cell Viability Assay[2] Cell Line: AML cell Concentration: 1, 10, 100 μM Incubation Time: 48 hours Result: Led to a dose-dependent decrease in proliferation in all cell lines.
In Vivo	SB-332235 (25 mg/kg, p.o., b.i.d.) exhibits significantly reduced numbers of total leukocytes in synovial fluids from IL-8-injected knees[1]. SB-332235 (10-25 mg/kg; p.o.; twice a day for 14 days) inhibits chronic Ag-induced arthritis[1]. Animal Model: Adult female New Zealand White rabbits (chronic OVA-induced model of arthritis)[1] Dosage: 10, 25 mg/kg Administration: P.o.; twice a day for 14 days Result: Day-15 synovial fluid leukocyte numbers in OVA-injected knees were significantly reduced in rabbits. The decrease in neutrophils, monocytes, and lymphocytes resulting from treatment with 25 mg/kg of the antagonist was accompanied by a significant reduction in synovial fluid PGE2, LTB4, LTC4, and IL-8 levels.
References	[1]. Podolin PL, et al. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002;169(11):6435-6444. [2]. Schinke C, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells [published correction appears in Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura]]. Blood. 2015;125(20):3144-3152.

Density	1.8±0.1 g/cm3
Molecular Formula	C₁₃H₁₀Cl₃N₃O₄S
Molecular Weight	410.660
Exact Mass	408.945770
LogP	3.75
Index of Refraction	1.719
Storage condition	2-8°C

Hazard Codes	Xi

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

276702-15-9	143797-62-0
201038-74-6	274252-40-3
1346603-08-4	1431697-90-3
200940-23-4	24570-77-2
791789-61-2	201038-58-6
2138280-05-2	2138509-82-5
2138520-43-9	2138261-58-0
2742021-75-4	2137628-88-5
2137144-79-5	2742010-88-2
2137729-92-9	2137793-60-1